Ascendis Pharma (ASND) Receives a Hold from Morgan Stanley
Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Ascendis Pharma (ASND – Research Report) today and set a price target of ...
Fierce Biotech4h
AstraZeneca's $800M rare disease bet hits primary phase 3 goal, but competitive strength still unclear
A phase 3 trial of AstraZeneca’s $800 million rare disease candidate has met its primary endpoint. The update keeps ...
Morgan Stanley Sticks to Their Buy Rating for Legend Biotech (LEGN)
In a report released today, Vikram Purohit from Morgan Stanley maintained a Buy rating on Legend Biotech (LEGN – Research Report), with a price ...
MT Newswires on MSN27m
European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading
European equities traded in the US as American depositary receipts kicked off the week higher late Monday morning, rising 1.12% to 1,433.84 on the S&P Europe Select ADR Index. From continental Europe, ...